365996-71-0

Basic information

• Product Name: Methyl 2-bromo-4-(2-methoxy-2-oxoethyl)thiazole-5-carboxylate
• Synonyms: Methyl 2-bromo-4-(2-methoxy-2-oxoethyl)thiazole-5-carboxylate
• CAS NO: 365996-71-0
• Molecular Formula: C8H8BrNO4S
• Molecular Weight: 294.124
• Mol File: 365996-71-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 369°C at 760 mmHg
• Flash Point: 177°C
• Appearance: /
• Density: 1.642g/cm³
• Vapor Pressure: 1.22E-05mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-bromo-4-(2-methoxy-2-oxoethyl)thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-bromo-4-(2-methoxy-2-oxoethyl)thiazole-5-carboxylate(365996-71-0)
• EPA Substance Registry System: Methyl 2-bromo-4-(2-methoxy-2-oxoethyl)thiazole-5-carboxylate(365996-71-0)

Safety Data

• Hazardous Substances Data: 365996-71-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H8BrNO4S/c1-13-5(11)3-4-6(7(12)14-2)15-8(9)10-4/h3H2,1-2H3

Upstream product

• 6506-30-5 2-amino-4-methoxycarbonylmethyl-thiazole-5-carboxylic acid methyl ester 

Relevant articles and documents

PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS

The present invention provides DNA Gyrase and/or Topo IV inhibitors of formula I, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonus spp., Acenetobacter spp., Muraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Mycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Cotyne bacterium, Bacillus spp., Enterobactericeae (E.coli, Klebsiella spp., Proteus spp.,etc.) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.